CHAIN DRUGSTORE Daily
BOSTON
AUG. 16, 2026
PROUD
A New Look for the Next Wave of Wellness
ASSOCIATE MEMBER FOR OVER A DECADE
Sun Pharma’s OTC Baby Care and Children’s Health Products
Oser Communications Group
embecta + Owen Mumford
BOOTH #1953
BOOTH #2031
BOOTH #769
Nature’s Truth® is arriving at this year’s show with a fresh new look and a growing portfolio designed to help retailers stand out in an increasingly competitive wellness category. The vitamin experts continue to gain momentum, growing double digits year over year and outpacing the overall vitamin category. Now,
Sun Pharma is offering a line of branded over-thecounter baby and children’s care products designed to support families with safe, effective solutions. FeverAll® is a trusted brand of acetaminophen suppositories available in infant, children and junior strength doses. Unlike liquid medications, FeverAll Acetaminophen
By Rachael Roberts, Vice President, U.S. Sales & Distribution, embecta In May, embecta and Owen Mumford announced an exciting milestone: the completion of embecta’s acquisition of Owen Mumford. This brings together two organizations that share a vision of developing innovative solutions to empower people with chronic conditions – including obesity, diabetes, autoimmune diseases and anaphylaxis – to live their lives with greater flexibility and confidence. Together, Owen Mumford and embecta offer a
Continued on Page 33
Continued on Page 30
Continued on Page 28
The Future of Central Fill Automation BOOTH #2255 An interview with Mike Futch, Chief Executive Officer of Tompkins Robotics.
Camber Consumer Care Creates Value in OTC Industry Digi Launches SmartSense ONE
BOOTH #1238
SmartSense by Digi®, part of Digi International, a leading global provider of Internet of Things (IoT) connectivity solutions, has unveiled SmartSense ONE, a modular, scalable solution that unifies the strengths of
Camber Consumer Care, a division of Camber Pharmaceuticals based in Piscataway, New Jersey, is an integral part of the Hetero family, one of the largest suppliers of APIs and FDF in India. Aligned with Hetero's mission, Camber Consumer Care is dedicated to ensuring consistent access to high-quality and
Continued on Page 33
Continued on Page 30
BOOTH #1117
CDD: What trends are you seeing in central fill automation today where T o m p k i n s Robotics plays a role? MF: Traditional central fill operations were typically built around fixed conveyor Continued on Page 30
4
Sunday, August 16, 2026
Chain Drugstore Daily
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin DexCom, Inc. announced results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically
significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a rou-
tine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of the American Diabetes Association in New Orleans. “The CONNECT study released today is the first and only level A evidence demonstrating strong benefit of CGM for the Type 2 non-insulin using population,” said Roy Beck, MD, PhD, Medical Director of the JAEB Center for Health Research and senior author of the study. “Level A evidence, the highest level of evidence graded by the ADA, has historically driven meaningful changes in standards of care.” CONNECT demonstrated clinically significant benefit for all adult Type 2 non-insulin using patients regardless of age, gender, ethnicity, baseline A1C,
body mass index, education level, income and insurance coverage.1 The study also showed an additional clinically significant reduction in A1C when using Dexcom G7 with various combinations of current standards of care diabetes medication, including metformin, GLP-1s and SGLT2s.1 “We anticipate these results will help establish a new standard of care in the United States and around the world,” said Jake Leach, President and Chief Executive Officer of Dexcom. “This is the third Dexcom sponsored randomized controlled trial that has or will drive Dexcom CGM to be the standard of care in people with Type 2 diabetes.” All CONNECT study participants were provided diabetes education on diet and exercise at the start of the study, given a blood glucose meter, and pre-study glucose lowering medications were continued. Half of the study participants were put on Dexcom G7 and half of them used self-monitoring of blood glucose. The CONNECT study initially screened 440 participants across 22 primary care practices throughout the United States, of which 283 eligible participants were randomized to Dexcom G7 or routine care, with 265 completing the 26-week study and Continued on Page 33
CHAIN DRUGSTORE
Daily PROUD NACDS ASSOCIATE MEMBER FOR OVER A DECADE Kimberly Oser Publisher Tara Neal President Abeer Abiaad Vice President Yasmine Brown Creative Director JoEllen Lowry Editor Marcos Morhaim Vice President of Sales Damaris Leon Stephanie Perez Account Managers customerservice@oser.com Customer Service logistics@oser.com Logistics Enrico Cecchi European Sales Chain Drugstore Daily is published by Oser Communications Group ©2026 All rights reserved. Executive and editorial offices at: 1877 N. Kolb Road, Tucson, AZ 85715 520.721.1300/Fax: 520.721.6300 European offices located at Lungarno Benvenuto Cellini, 11, 50125 Florence, Italy www.osercommunicationsgroup.com
Lee M. Oser Founder
9
Chain Drugstore Daily
Beyond the Travel Aisle: Why Nausea Relief Is Becoming an Everyday Need Nausea has often been treated as a travel purchase. It is something shoppers remember before a flight, a cruise or a long car journey. But that is only one part of the story. For many people, nausea shows up during far more ordinary moments: on the commute, after lunch, during the school run or halfway through a busy day at work. It not always is planned for, and it is not always linked to travel. That matters retailers. for Digestive wellness is becoming a bigger part of everyday self-care, and shoppers are more aware than ever of the issues that can affect how they feel day to day. The growing conversation around GLP-1 medications has added to that awareness, with nausea now part of many more conversations about digestive comfort and routine healthcare. So the question for retailers is simple: does nausea relief still belong only in the travel aisle? Travel health will always be important, especially around holiday periods. But there is also a strong case for thinking about nausea relief as part of everyday wellness. Shoppers may be looking for something they can keep in a handbag, work bag, car, pocket or desk drawer. Not just something they buy before going away. Format plays a big role here. When nausea comes on suddenly, people usually want something simple. They may not want to swallow a tablet, wait for a lozenge to dissolve or find water before taking something. A small, dis-
creet, non-drowsy option that can be used on the go makes sense for the way people live now. Ginger is already familiar to many shoppers. It is an ingredient they recognise and understand, which makes it easier to navigate at shelf and easier for retailers to position clearly. Sea-Band® is building on that familiarity with the upcoming launch of SeaBand Liqui-Burst™ Gingers, expected in 2027. The new liquid-centre format is designed to release liquid ginger from the very first bite. Each piece delivers 375mg of ginger root powder equivalent in a compact, non-drowsy chew that can be taken without water. For buyers, the opportunity is not just about adding another travel product. Liqui-Burst Gingers give retailers a way to connect travel health with everyday digestive wellness and family healthcare. They are designed for the shopper who wants something practical, portable and easy to keep close by, whether they are travelling or simply getting through the day. Sea-Band is previewing Liqui-Burst Gingers alongside its established drugfree nausea relief range at this year’s show. Retailers, distributors and category managers are invited to visit Emerson booth #138 to see the new format and discuss the 2027 launch. For more information, go to www .sea-band.com, email hq@sea-band.com or stop by booth #138.
Dulcolax Introduces New Daily Gut Support Gummies Designed to fit into your daily wellness routine, Dulcolax Daily Gut Support* Gummies come in two flavors: ultradelicious berry and orange. These gummies help keep your gut running smoothly*. With Daily Gut Support Gummies, Dulcolax shows that gut support can be approachable, flavorful and an integral part of modern self-care. Take the first step toward feeling good from the inside out with Dulcolax Daily Gut Support* Gummies*†.
For more information, go to www.dulcolax .com/en-us or stop by booth #1201. * These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. † Based on a 2-week in-home use test with 203 adults.
12
Sunday, August 16, 2026
Chain Drugstore Daily
New Generic Launches – Dapagliflozin & Dapagliflozin/Metformin HCl Tablets Ascend Laboratories is introducing Dapagliflozin Tablets, 5 mg/10 mg bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Farxiga Tablets, 5 mg/10 mg, and Dapagliflozin and Hydrochloride Metformin Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg,10 mg/500 mg, and 10 mg/1,000 mg bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xigduo XR Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg and 10 mg/1,000 mg; indicated as an adjunct to diet and exercise to improve glycemic control in adults
with type 2 diabetes mellitus. These
products are now available. These products provide your phar-
ChapStick Introduces Hydrabalm Tubes and Debuts Refreshed Brand Look ChapStick is expanding its lip care portfolio with the launch of ChapStick Hydrabalm Tubes, a new squeezable format from America’s No. 1 lip balm brand (Units sold, Nielsen data L52 March 2026). The launch marks a new product format for the brand, trusted by consumers for more than 145 years to relieve dry, chapped lips. Hydrabalm offers the familiar moisturizing care people expect from ChapStick in a convenient tube designed for everyday use. The new line is available in five varieties: Vanilla, Cherry, Guava, Watermelon and Fragrance-Free Lip Repair. Retailing for under $4, Hydrabalm is positioned as an accessible option within the lip care category. Hydrabalm arrives as ChapStick rolls out a refreshed look across its portfolio. The updated packaging introduces a more modern visual identity while maintaining the same trusted formulas.
with every squeeze. Enriched with jojoba oil and shea butter, the formulas leave lips feeling softer, smoother and nourished. • Hydrabalm Lip Repair: FragranceFree: For consumers seeking more targeted care, Hydrabalm Lip Repair offers a fragrance-free formula designed for
What's New? • New Hydrabalm Tubes: ChapStick Hydrabalm Tubes bring a squeezable format to the brand's lip care lineup, combining crave-worthy flavors with the moisturizing performance ChapStick is known for. Formulated without parabens, sulfates or phthalates, Hydrabalm moisturizes lips for up to 24 hours and helps keep them feeling soft and smooth throughout the day. • Hydrabalm Flavors: Cherry, Vanilla, Guava and Watermelon – the flavored Hydrabalm varieties are designed for dry lips and deliver lasting moisture
severely dry lips. Enriched with vitamin E and shea butter, the formula provides soothing moisture and lasting comfort while helping restore softer, smootherlooking lips. • New Look, Same Formula: A refreshed brand identity is also coming to the broader ChapStick lineup across everyday classics, seasonal favorites, and new flavor assortments. The brand's classic stick multipacks will continue to deliver all-day moisture in familiar formulas, with three-packs retailing for under $4. • From classic favorites to fruitinspired varieties, ChapStick is posi-
macies with high quality, affordable alternatives in a key diabetes therapeutic class, supporting improved patient access and strong generic conversion opportunities. Ascend Laboratories is committed to delivering high quality, FDA approved generic pharmaceuticals supported by robust manufacturing, reliable supply and exceptional customer service. Ascend Laboratories appreciates your partnership and looks forward to supporting your business with this new product offering. If you have any questions regarding these products, contact your account executive or the customer service team. Ascend Laboratories’ sales and customer service teams are fully prepared to support your onboarding, forecasting and ordering needs. For more information, go to www.ascendlaboratories.com or stop by booth #1663. tioned to meet a range of consumer needs, occasions and preferences, whether at home, at work or on the go. About ChapStick ChapStick is part of the newly merged Evermark portfolio from Yellow Wood Partners. Since 1880, the brand has delivered dependable hydration and protection, earning its place as America's No. 1 lip balm brand (Units sold, Nielsen data L52 March 2026). As a pioneer of the lip
balm category, ChapStick continues to lead with science-backed formulas designed to provide long-lasting moisture, relief and repair. From classic favorites to innovative new formats and flavors, ChapStick remains focused on delivering exactly what lips crave. ChapStick products are available at retailers across the United States, including Walmart, Dollar General, Target, CVS, Walgreens, Family Dollar, Kroger and Amazon. For more information, go to www .chapstick.com or stop by booth #138.
20
Sunday, August 16, 2026
Chain Drugstore Daily
Studies Confirm Concentrated Heat Rapidly Reduces Insect Bite Itch Without Drugs or Chemicals
Camber Specialty Growing Portfolio Camber Specialty, established in 2022 by Hetero and Camber Pharmaceuticals, is dedicated to meeting the increasing demand for generic specialty and oncology products in healthcare settings. Hetero, the parent organization, is committed to launching around 50 specialty products by 2028. The focus of Camber Specialty is on research and development, investing over $250 million in portfolio expansion and nearly $500 million in corporate infrastructure to address the growing market demand. Hetero's injectable manufacturing facility is well-equipped to produce 90 million units of liquid injectables, 60 million units of lyophilized injectables, and 20 million units of powder injectables annually. Anticipating that approximately 65% of new drugs in the U.S. market are expected to be specialty pharmaceuticals, the company is strategically positioned to contribute significantly to this segment. Oncology care is a central aspect of Camber Specialty's goals with a deep pipeline of generic products being developed. As a global supplier of criti-
cal care products, including those for rare disease therapies, the company aims to bring important generic injectable molecules to the market. Camber Specialty places a strong emphasis on partnerships, highlighting communication and transparency as core values. The company’s strategic account management teams work to enhance collaboration and information flow with partners, aiming to mitigate risks for distributors. With a proven track record of maintaining a 99% service level in primary positions across its portfolio, Camber underscores its commitment to quality, supply and service. The company’s success comes from strong vertical integration across R&D, API and KSMs, ensuring an excellent supply chain. Camber Specialty extends this commitment, aiming to make affordable specialty medicines accessible to patients throughout the United States. For more information, go to www .camberpharma.com or stop by booth #1238.
Two independent scientific studies have confirmed that the targeted application of concentrated heat to an insect bite significantly reduces itch intensity within minutes, outperforming untreated controls and requiring no medication, cream or chemical of any kind. The findings come from Beurer, the German health technology company that pioneered the modern heating pad more than a century ago and has now applied that precision thermal science to one of the most common dermatological complaints worldwide. The first study, a controlled clinical trial conducted by Institut Prof. Kurscheid and registered with the German Clinical Trials Register (DRKS00033004), enrolled 22 participants – 15 women and seven men with an average age of 28 – who were bitten under controlled laboratory conditions by two mosquito species. The results were clear: within just two minutes, people using the BiteX Insect Bite Healer (BR60) reported itch scores nearly half those of the untreated group (2.40 versus 4.30 on a 10-point scale). Over the full 60-minute observation period, treated bites produced an average itch exposure score of 97, compared with 161 for untreated bites – a difference that was statistically significant (p<0.01). In more than six in 10 observations, treated bites achieved at least a 50% reduction in itch at the very first measurement point. No adverse events were reported. The second study, published in Acta Dermato-Venereologica by researchers
from Charité Universitätsmedizin Berlin and the Fraunhofer Institute, tracked more than 12,000 treatments across 1,750 participants. Mosquito bite itch dropped 57% within the first minute and 81% within five to 10 minutes. Participants who applied heat showed 7.1 times greater itch reduction at one minute compared to an untreated control group. The heat worked equally well whether applied minutes or more than six hours after the bite. Both studies point to a neurological rather than pharmacological mechanism. Researchers note that concentrated heat activates TRPV1 nerve receptors, which override and suppress the itch signal before the brain processes it as discomfort, a process known as counter-stimulation. The effect works on both histamine-driven and non-histamine itch, covering the full range of reactions from mosquitoes, bees, wasps and horseflies. The safety profile across both studies was exceptional. The clinical trial recorded zero adverse events across 44 observations. The Charité-Fraunhofer study documented side effects in fewer than 0.13% of more than 48,000 data points, with none classified as serious. The absence of systemic effects makes thermotherapy particularly relevant for pregnant women, young children and patients managing multiple medications, populations for whom standard topical treatments are often limited or contraindicated. For more information, go to www .shop-beurer.com.
Sunday, August 16, 2026
Chain Drugstore Daily
FDA Grants Priority Review to Genentech’s Gazyva for Adults With Primary Membranous Nephropathy Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the company’s supplemental Biologics License Application (sBLA) for Gazyva® (obinutuzumab) for the treatment of primary membranous nephropathy (pMN). The priority review is based on the positive Phase III MAJESTY results, which show superiority of Gazyva over an immunosuppressive therapy, tacrolimus, in adults with pMN. The FDA has already granted Breakthrough Therapy Designation (BTD) to Gazyva in pMN and is expected to make a decision on approval by November 2026. This is the second indication in recent months for which the U.S. FDA has granted priority review to Gazyva following idiopathic nephrotic syndrome in May 2026. “This priority review represents an important step for patients living with primary membranous nephropathy, a chronic disease with no FDA-approved treatments,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “By targeting tissue-resident B cells, Gazyva addresses an underlying cause of pMN and has the potential to help more patients achieve complete remission – a necessary step to maintaining kidney function.” The Phase III MAJESTY study met its primary endpoint with 36.9% of adults achieving complete remission (CR) at two years (104 weeks) with Gazyva versus 5.7% with tacrolimus (adjusted difference 31.1%; 95% confidence interval [CI] 18.2 to 44.0;
p<0.001). Complete remission is the ultimate goal in pMN and can help prevent progression to kidney failure. Key secondary endpoints showed that Gazyva was superior to tacrolimus in achieving overall remission (complete or partial remission) at week 104 and complete remission at week 76. Safety was in line with the well-characterized profile of Gazyva and no new safety signals were identified. The data were featured at the 63rd European Renal Association (ERA) Congress in June 2026 as a late-breaking oral presentation and published in the New England Journal of Medicine (NEJM). In April 2026, the FDA granted Breakthrough Therapy Designation for Gazyva in pMN. Data from MAJESTY are also being submitted to other global health authorities, including the European Medicines Agency. pMN is a chronic autoimmune condition that causes potentially irreversible kidney damage and can lead to kidney failure, which has a significant impact on patients and their families, while carrying substantial burden to health systems. Achieving complete remission is important to help maintain kidney function and delay or prevent the onset of serious and potentially fatal complications. MAJESTY is the fourth positive Phase III study of Gazyva in immunemediated diseases, following REGENCY in lupus nephritis, ALLEGORY in systemic lupus erythematosus (SLE) and INShore in idiopathic nephrotic syndrome – where it received priority
review and Breakthrough Therapy Designation by the FDA. Gazyva is approved in the United States and European Union for the treatment of adults with active lupus nephritis who are receiving standard therapy based on data from the REGENCY and NOBILITY studies, and is being investigated in the Phase II POSTERITY study for children and adolescents with lupus nephritis. This growing body of evidence supports Gazyva’s potential in addressing disease activity across a spectrum of immune-mediated diseases. About Gazyva Gazyva (obinutuzumab) is a humanized monoclonal antibody designed with a Type II anti-CD20 region, for direct B cell death and a glycoengineered Fc region, for higher binding affinity and increased antibody-dependent cellular cytotoxicity (ADCC). CD20 is a protein found on certain types of B cells. Gazyva is approved for adults with lupus nephritis in the United States and European Union. Gazyva is also approved in 100 countries for various types of hematological cancers. About the MAJESTY Study MAJESTY [NCT04629248] is a Phase III, randomized, open-label, multicenter study designed to evaluate the efficacy
25
and safety of Gazyva (obinutuzumab) in adults with primary membranous nephropathy. The study enrolled 142 adults who were randomized 1:1 to receive Gazyva or tacrolimus. The primary endpoint is the percentage of adults who achieve complete remission at two years (week 104). About Primary Membranous Nephropathy Primary membranous nephropathy is a chronic autoimmune condition where the body’s immune system attacks the filtering units of the kidney, the glomeruli, causing protein to leak into the urine and potentially a gradual decline in kidney function. Over time, the damage to the kidneys can become irreversible, increasing the risk of lifethreatening complications, such as kidney failure, idiopathic nephrotic syndrome, blood clots and cardiovascular disease. Achieving complete remission is important to help maintain kidney function and delay or prevent the onset of serious and potentially fatal complications. Primary membranous nephropathy has an estimated incidence of 1.2 per 100,000 people in the United States per year. For more information, www.gene.com.
go
to
28
Chain Drugstore Daily
Stellar Beauty Co. Launches to Redefine Skincare for Active Girls Stellar Beauty Co. officially launches with a mission to redefine what skincare looks like for the next generation. Created by 12-year old athlete and Founder Stella Dorazio, the brand introduces a collection of dermatologist-tested skincare products designed specifically for active girls and growing skin – bringing together gentle ingredients, mineral sun protection and healthy habits in one easy-to-follow routine. Inspired by Stella’s own experience balancing sports, school, camps and everyday adventures, Stellar was born from a simple realization: while the beauty industry has embraced the growing interest in tween skincare, there were few options created specifically for girls with active lifestyles. Rather than adapting products made for adults, Stellar was developed from
the ground up to support what the brand calls “Active Skin” – skin exposed to sweat, sun, chlorine, wind and the everyday demands of growing up. “Stellar started because I wanted skincare that felt like it was made for girls like me,” said Stellar Beauty Co.’s Founder, Stella. “I wanted products that were fun and easy to use, but also gentle enough for growing skin and designed for all the things I love to do. I hope Stellar helps other girls build confidence through simple, healthy habits and reminds them to always shine as themselves.” Stellar Beauty Co.’s debut collection features four daily essentials: • Passion Pop Smash Cleanser ($17) – A gentle, hydrating cleanser formulated to effectively
embecta (Cont’d. from p. 1)
global commercial reach, distribution infrastructure and large-scale manufacturing expertise, embecta and Owen Mumford are well positioned to accelerate innovation and scale. Building on more than 170 years of combined experience, embecta and Owen Mumford will work together to identify unmet healthcare needs and develop meaningful solutions for patients and healthcare providers worldwide. While Owen Mumford is now part of embecta, both organizations currently operate independently, and it remains business as usual for our customers and partners. We remain committed to delivering the same high levels of service and continuity and will keep you informed about the opportunities this combination will bring.
broader portfolio of clinically relevant products. embecta is a global leader in insulin injection, manufacturing pen needles and syringes that are used by more than 30 million people in more than 100 countries. Owen Mumford brings a diverse and well-established portfolio spanning drug delivery, blood collection, ophthalmology, podiatry and pelvic health, including auto-injectors, safety devices and advanced blood sampling solutions. The acquisition includes a differentiated drug-delivery platform designed to support pharmaceutical partners across multiple therapeutic areas alongside a strong underlying intellectual property portfolio, including the next-generation Aidaptus® auto-injector platform. By combining Owen Mumford’s expertise in device design, molding and assembly with embecta’s
Continued on Page 30
For more information, go to www .embecta.com or stop by booth #769.
30
Sunday, August 16, 2026
Sun Pharma (Cont’d. from p. 1)
Suppositories provide accurate, messfree dosing – eliminating concerns of under-dosing due to spitting out, vomiting or refusal of oral medicine. Caregivers can confidently manage their child’s fever and minor pain anytime, especially when oral administration isn’t an option. Expanding its fever care solutions, FeverAll Liquid Oral Acetaminophen is available in kid-friendly cherry and grape flavors. It’s formulated to temCamber Pharmaceuticals (Cont’d. from p. 1)
affordable OTC medicines, contributing to the well-being of patients throughout the United States. Strategic Partner Functioning as a strategic supplier, Camber Consumer Care caters to retailers seeking high quality, private label OTC medications. By doing so, it both creates value for its partners and delivers cost savings to consumers. The company’s primary focus areas include Allergy, Pain, Gastrointestinal and Cough & Cold relief, offering dosage Tompkins Robotics (Cont’d. from p. 1)
systems, sequential workflows and inflexible systems. These are difficult and expensive to expand or reconfigure as volumes grow or fulfillment strategies evolve. Instead of simply adding capacity, businesses often have to redesign their infrastructure. The solution to this is to automate using robotic systems such as Tompkins tSort solutions. We provide automated robotic transport and sortation systems that replace the conveyors used to move individual scripts throughout the operation and sort the outbound patient orders to stores. CDD: What should fulfillment leaders prioritize when evaluating automation? MF: We encourage leaders to look at flexibility, scalability, infrastructure required, deployment time, mainteStellar Beauty (Cont’d. from p. 28)
cleanse without stripping the skin barrier. • Coco Rush Punch Moisturizer ($18) – A lightweight daily moisturizer that delivers lasting hydration while supporting the skin’s natural moisture barrier. • Splash Face Mist ($16) – A refreshing, after-sun facial mist designed to instantly hydrate and comfort skin after outdoor activities. • Glow Guard Mineral Sunscreen SPF 50 ($27) – A broad-spectrum mineral
Chain Drugstore Daily porarily relieve fever, minor aches and pains, headaches, toothaches and sore throats. Gentle on the stomach, it’s free from ibuprofen, aspirin and alcohol – offering a safe, effective choice for little ones. bébé Bottoms® offers gentle, effective skincare for babies. The line includes bébé Bottoms Diaper Rash Crème Spray and new Skin Care Baby Wipes. bébé Bottoms Diaper Rash Crème Spray is a soothing, easy-to-use spray formulated for delicate skin. Unlike
thick diaper rash creams, it features a proprietary TLC – Thin Layer Care™ technology, delivering the efficacy of a rich cream in a light, breathable spray. With organic chamomile and calendula to calm and moisturize, and 10% zinc oxide to create a protective barrier against moisture, it helps support the skin’s natural healing process. bébé Bottoms Skin Care Baby Wipes are crafted with care for sensitive skin. Enriched with soothing botanical extracts like chamomile, cal-
forms such as tablets, capsules, powders, solutions and suspensions. Maintaining an unwavering commitment to quality, Camber Consumer Care adheres to the highest manufacturing standards concerning health, safety and environmental practices.
onorgestrel tablets as a safe and affordable emergency contraceptive product.
Recent & Upcoming Launches Camber Consumer Care has been shifting their product development focus to more clean and clear OTC products – free of sugars, dyes and other synthetic ingredients, especially for private labeled products. The company plans to launch levnance requirements and total cost of ownership. Ask yourself: how easily can this system adapt to business changes? The automation you install today should still support your operation years from now. Another key item is the cost of delivery to patients. Your automation should drive reductions in manual labor, operating, facility and ongoing costs. CDD: How does modular robotic automation change the equation?
Distinct Advantage Camber Consumer Care's distinct advantage lies in its technical and global resources, including facilities and joint ventures in the United States, India, South America, Spain and the Middle East. The company exercises unparalleled control over every aspect of the supply chain, from active pharmaceutical ingredients to finished dosage form and packaging. Supported by a proven team of experienced professionals in the OTC private structure additions, costs or downtime. CDD: Where does tSort fit into your client’s central fill operations? MF: We move individual scripts from automated and manual filling to downstream automated bagging and order consolidation replacing conveyors. We also provide order consolidation using our tSort3D system. And finally, we sort outbound patient orders to thousands of stores in a typical facility.
MF: Modular robotic systems, like Tompkins Robotics tSort, remove much of the fixed infrastructure that limits traditional facilities. Autonomous robots transport and sort scripts and orders dynamically, allowing multiple workflows to operate in parallel instead of a single sequential path. This reduces bottlenecks while making it easier to expand capacity or reconfigure operations without major infra-
MF: Accuracy and consistency are critical in pharmaceutical fulfillment. Reducing manual touches helps minimize opportunities for error, while automation provides greater visibility into where orders are throughout the
sunscreen featuring 17.5% zinc oxide, SPF 50 protection, up to 80 minutes of water resistance, and a sheer, nowhite-cast finish. Every product is dermatologist tested and developed with Stellar’s proprietary Glow-Safe Formula™, prioritizing gentle, age-appropriate ingredients while excluding retinoids, parabens, synthetic fragrances and other unnecessary actives often found in products designed for adults. Across the collection, barrier-supporting hydration technologies, antioxidantrich botanicals and mineral sun protec-
tion work together to help keep growing skin healthy, comfortable and protected. Beyond its formulas, Stellar Beauty promotes ingredient transparency through its Glow Strong. Shine Bright.™ approach, breaking down what key ingredients are and how they support growing skin in clear, easy-tounderstand language so girls and parents can feel confident in every GlowSafe Formula. As conversations around tween skincare continue to evolve, Stellar offers a different perspective – one
CDD: Beyond productivity, where can automation create the biggest impact?
endula and aloe, these wipes gently cleanse while calming and nourishing. Free from parabens, dyes and fragrances, they’re hypoallergenic and safe for everyday use – perfect for diaper changes, hands, faces and other delicate areas. Thoughtfully packaged in 100% plant-based, plastic-free materials, they reflect a commitment to both family wellness and environmental responsibility. For more information, stop by booth #2031. label space, Camber Consumer Care bridges the gap between prescription and OTC product offerings. Private Label Opportunities Camber Consumer Care has in-depth experience with private-label partnerships and currently supplies a variety of products to more than 5,600 major retail outlets. For private label opportunities, email info@cambercc.com or call 732.529.0430. For more information, go to www .camberpharma.com or stop by booth #1238. fulfillment process. Faster deployment is another benefit that often gets overlooked – getting a system operational sooner means organizations begin realizing value much earlier. CDD: What advice would you give pharmaceutical fulfillment leaders planning for the future? MF: Design for change. Patient expectations, prescription volumes and fulfillment models will continue to evolve. The most successful operations won't necessarily be the ones with the biggest systems – they'll be the ones with automation that can adapt quickly. Investing in flexible, scalable technology today positions your operation to respond to whatever tomorrow brings. For more information, go to www .tompkinsrobotics.com or stop by booth #2255. rooted in wellness rather than beauty standards. Instead of encouraging complicated routines or trend-driven ingredients, the brand aims to help girls build healthy habits centered on cleansing, hydration, and daily sun protection. “Skincare shouldn’t feel intimidating or be about chasing perfection,” said Stella. “It’s about taking care of yourself, feeling confident, and creating routines that help you feel your best.” For more information, go to www .stellarbeautyco.com.
Sunday, August 16, 2026
Chain Drugstore Daily SmartSense (Cont’d. from p. 1)
SmartSense and Jolt’s platforms by connecting their monitoring, operations, safety and quality capabilities through a shared data model and a common user experience. The launch of SmartSense ONE comes on the heels of Digi’s acquisition of Jolt and the integration of its food safety and operational improvement platform into the SmartSense business. Combined, SmartSense and Jolt help chain pharmacies and healthcare organizations protect revenue and reduce risk by ensuring critical assets and environments stay within compliance and operating standards. Their unified solution delivers prescriptive analytics, automated monitoring and actionable workflows that help teams prevent spoilage, avoid equipment downtime, maintain medication safety and regulatory compliance, and respond faster to issues, before they become costly disruptions. Nature’s Truth (Cont’d. from p. 1)
Nature’s Truth is taking the next step in its evolution with a packaging refresh designed to deliver stronger shelf presence and greater consumer engagement. Soon, the entire Nature’s Truth line will transition to sleek cylinder bottles featuring vibrant, full coverage shrink sleeve labels. The new packaging creates a more distinctive and premium appearance on-shelf, helping Nature's Truth products stand out in crowded vitamin aisles while making key product benefits easier for shoppers to identify. “Today’s consumers are navigating more choices than ever before and making decisions quickly at shelf,” said Dexcom (Cont’d. from p. 4)
analyzed for the key outcomes reported at ADA. Key outcomes from the study include1: • Average 1.6% A1C reduction with Dexcom G7 from baseline mean A1C of 8.8%. ○ Participants using Dexcom G7 experienced on average a 1.6% A1C reduction at 26 weeks, representing a 0.9% greater A1C reduction compared to the control group. ○ Participants using Dexcom G7 with an initial A1C > 10% experienced on average a 3.1% A1C reduction, representing a 2.1% greater A1C reduction compared to the control group. ○ 82% of participants had a clinically and statistically significant lower A1C of at least 0.5%. • 68% of participants using Dexcom G7 reached <7.5% A1C at 26 weeks and 46% reached < 7.0% A1C at 26 weeks, demonstrating both clinically and statistically significant reductions.
33
SmartSense ONE unifies both companies’ capabilities within seven core modules that are intentionally designed to work together, creating a more powerful, connected platform for SmartSense customers. Customers can deploy modules based on their operational needs, but the greatest impact comes from using them in combination. Core modules include: • Monitor: An asset management and visibility module comprised of features that deliver real-time prescriptive analytics into asset health and environmental conditions with predictive insights and automated actions • Operate: An operations and task management module comprised of checklists, tasks and standard operating procedures (SOPs) with real-time accountability, insights and performance tracking across every location • Guard: A food safety and compliance monitoring module with probe and sensor integration for accurate,
auditable tracking and corrective action guidance • Assure: A compliance and quality audit oversight module comprised of digital audits, inspections, and follow-up actions that ensure continuous improvement for the scaled environment • Service: A maintenance and asset management module comprised of issue prevention, work orders and asset tracking features that reduce downtime and improve equipment reliability • Label: A labeling and printing module that automates labeling, ensures compliance and streamlines prep workflows, integrated with the other modules • Schedule: A labor and shift management module comprised of scheduling, time tracking and team communication that improves efficiency, compliance and employee engagement
nance and trust by allowing customers to embed automated compliance validation, traceability and audit-ready reporting to meet regulatory standards with confidence. Whether customers use one module or all seven, they will have access to several of the same best-in-class SmartSense ONE capabilities via a single, intuitive interface that works across web and mobile, streamlines tasks and drives adoption from deskless workers to executives. SmartSense ONE’s data model provides real-time monitoring, audit and workflow data for all customers, uncovering predictive insights that anticipate risks and guide smarter operational decisions. The platform also works seamlessly online or offline, maintaining visibility and control across every site and condition.
SmartSense ONE boasts industry-leading capabilities for compliance, gover-
For more information, go to www.smart sense.co or stop by booth #1117.
Kimberly Vigliante, Senior Vice President of Sales & Marketing. “The new Nature’s Truth packaging was designed to create stronger shelf impact, improve benefit communication and make it easier for shoppers to find the wellness solutions they’re looking for. By enhancing both visibility and navigation, we’re creating a better shopping experience while helping our retail partners drive category growth.” The refreshed look arrives alongside one of the brand's most ambitious innovation pipelines to date. Nature’s Truth is launching a broad range of trend-forward formulas built around the high-growth segments retailers are prioritizing: mood and stress support, healthy aging, sleep, energy, women’s
health and gut health. Standout additions include the Saffron + Magnesium Glycinate Capsules, featuring a three-ingredient blend including methylated B12 and tapping into the fast-growing mood and relaxation support segment. Rounding out the launch is the NAD+ Collagen Complex, a triple-action healthy aging formula combining NAD+, collagen and resveratrol. Additional launches across sleep, probiotics and liquid supplements further expand the brand’s ability to meet evolving consumer needs. The Liquids category continues to be a major growth driver for Nature’s Truth, with its liquid products increasing 362.5% year over year. New liquid offerings include organic concentrated
elderberry extract, L-theanine liquid drops, oil of oregano and liquid chlorophyll, positioning retailers to capitalize on growing consumer demand for convenient supplement formats. Backed by generations of vitamin innovation and expertise, Nature’s Truth brings category authority, speed to market and a pipeline of popular products that resonate with today's shopper. With competitive pricing, including strong BOGO promotional pricing that gives retail partners a meaningful point of difference at shelf, Nature’s Truth looks forward to continued innovation and shared growth.
• The use of Dexcom G7 alone lowered A1C more than any other medication treatment group with a 2.4% reduction in A1c compared to 1.5% in the control group. • The use of Dexcom G7 had an additive effect in lowering A1C across all medication groups. ○ In participants using GLP-1s, using Dexcom G7 resulted in a 1.4% reduction in A1C compared to 0.2% in the control group. ○ In participants using SGLT2s, using Dexcom G7 resulted in a 1.8% reduction in A1C compared to 0.7% in the control group. • Time in the glucose target range of 70 to 180 mg/dL was five hours per day greater for participants using Dexcom G7 compared to the control group. ○ Those using Dexcom G7 observed overall a clinically significant time in range improvement as early as 1-4 weeks and sustained it through 26 weeks. ○ On average at the end of 26 weeks, participants using Dexcom G7
achieved 62% time in range compared to 41% in the control group. • Participants using Dexcom G7 reported a greater satisfaction with the use of Dexcom CGM compared to those using self-monitoring of blood glucose and reduced diabetes distress and disease burden. ○ There was a median Dexcom G7 daily usage of 97% throughout the 26week study. A six-month extension phase of the CONNECT randomized controlled trial is currently being conducted, which will provide further data on the sustainable benefits of Dexcom G7 up to 12 months. The CONNECT study is of similar magnitude to previous randomized controlled trials, such as JDRF, DIAMOND and MOBILE, which demonstrated the benefits of CGM use among insulin using people with diabetes and helped define CGM as the standard of care for people with Type 1 and Type 2 diabetes on intensive and basal insulin.
For more information, go to www .naturestruth.com or stop by booth #1953. About Dexcom Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. For more information, go to www .dexcom.com or stop by booth #1368. Press release: https://investors.dexcom.com/ news/news-details/2026/Dexcom-CONNECTStudy-The-Most-Significant-Clinical-StudyDemonstrating-CGM-Benefits-for-People-withType-2-Diabetes-Not-Using-Insulin/default.aspx Category: IR 1Oser T, et al. CGM for Adults with Type 2 Diabetes Not on Insulin: The CONNECT Randomized Controlled Trial. Presented at the 2026 Scientific Sessions of the American Diabetes Association, June 6, 2026. New Orleans, LA; USA.